Literature DB >> 12456578

Osteogenesis imperfecta and intravenous pamidronate.

I Banerjee, G J Shortland, W D Evans, J W Gregory.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456578      PMCID: PMC1755843          DOI: 10.1136/adc.87.6.562-a

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  6 in total

Review 1.  Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors:  J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal:  Arch Dis Child       Date:  2006-05-11       Impact factor: 3.791

Review 2.  Osteogenesis imperfecta: new treatment options.

Authors:  Guillaume Chevrel; Rolando Cimaz
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

3.  Complications of pamidronate therapy in paediatric osteoporosis.

Authors:  Sanjay K Chilbule; Vrisha Madhuri
Journal:  J Child Orthop       Date:  2012-01-29       Impact factor: 1.548

4.  The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.

Authors:  Demetris Delos; Xu Yang; Benjamin F Ricciardi; Elizabeth R Myers; Mathias P G Bostrom; Nancy Pleshko Camacho
Journal:  J Orthop Res       Date:  2008-02       Impact factor: 3.494

Review 5.  Pharmacological interventions for pain in children and adolescents with life-limiting conditions.

Authors:  Emma Beecham; Bridget Candy; Richard Howard; Renée McCulloch; Jo Laddie; Henrietta Rees; Victoria Vickerstaff; Myra Bluebond-Langner; Louise Jones
Journal:  Cochrane Database Syst Rev       Date:  2015-03-13

6.  A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America.

Authors:  Arzu Soybilgic; Melissa Tesher; Linda Wagner-Weiner; Karen B Onel
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-09       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.